Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yongsheng Huang is active.

Publication


Featured researches published by Yongsheng Huang.


Oncogene | 2005

ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.

Atsushi Suzuki; Shinsuke Iida; Emi Tajima; Fenghuang Zhan; Ichiro Hanamura; Yongsheng Huang; Tsutomu Ogura; Satoru Takahashi; Ryuzo Ueda; Bart Barlogie; John D. Shaughnessy; Hiroyasu Esumi

ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found ARK5 expression in multiple myeloma cell lines expressing c-MAF and MAFB. In addition, gene expression profiling of 351 clinical specimens revealed ARK5 expression in primary myelomas expressing c-MAF and MAFB, suggesting that ARK5 may be a transcriptional target of the Large-MAF family. Sequence analysis of the ARK5 gene promoter revealed that it contains two putative MAF-recognition element (MARE) sequences. In support of this hypothesis, ARK5 was induced when an MAFB or c-MAF expression vector was introduced into non-ARK5-expressing colon cancer cells. Furthermore, ARK5 promoter activity was dramatically decreased by mutation or deletion of MARE sequences. Chromatin immunoprecipitation assays revealed an interaction between the Large-MAF family proteins and MARE sequences in the ARK5 promoter. Moreover, in ARK5 mRNA-expressing multiple myeloma lines, but not in ARK5-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity. IGF-1-induced invasion was reproduced when ARK5 was overexpressed in Burkitts lymphoma and plasmacytoma lines. Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.


Leukemia | 2006

Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.

Ichiro Hanamura; Yongsheng Huang; Fenghuang Zhan; B Barlogie; John D. Shaughnessy

Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations


Blood | 2006

The molecular classification of multiple myeloma

Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P. Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey R. Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D. Shaughnessy


Blood | 2007

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

John D. Shaughnessy; Fenghuang Zhan; Bart Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P. Stewart; Bob Kordsmeier; Christopher Randolph; David R. Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G. Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey R. Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie


Cancer Cell | 2006

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

Daniel R. Carrasco; Giovanni Tonon; Yongsheng Huang; Yunyu Zhang; Raktim Sinha; Bin Feng; James P. Stewart; Fenghuang Zhan; Deepak Khatry; Marina Protopopova; Alexei Protopopov; Kumar Sukhdeo; Ichiro Hanamura; Owen Stephens; Bart Barlogie; Kenneth C. Anderson; Lynda Chin; John D. Shaughnessy; Cameron Brennan; Ronald A. DePinho


Blood | 2006

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura; James P. Stewart; Yongsheng Huang; Fenghuang Zhan; Madhumita Santra; Jeffrey R. Sawyer; Klaus Hollmig; Maurizio Zangarri; Mauricio Pineda-Roman; Frits van Rhee; Federica Cavallo; Bart Burington; John Crowley; Guido Tricot; Bart Barlogie; John D. Shaughnessy


Blood | 2007

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

George Mulligan; Constantine S. Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J. Chng; Steven Roels; Erik Koenig; Andrew M. Fergus; Yongsheng Huang; Paul G. Richardson; William L. Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D. Shaughnessy; Leif Bergsagel; David P. Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C. Anderson


Blood | 2007

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

Fenghuang Zhan; Bart Barlogie; Varant Arzoumanian; Yongsheng Huang; David R. Williams; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Maurizio Zangari; Madhav V. Dhodapkar; John D. Shaughnessy


Blood | 2004

Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.

Fenghuang Zhan; Jeffrey R. Sawyer; Sushil Gupta; Yongsheng Huang; Elias Anaissie; Hongwei Xu; Ichior Hanamura; Madhumita Santra; Maurizio Zangari; Choon-Kee Lee; Athanasios Fassas; Frits van Rhee; Klaus Hollmig; Giampaolo Talamo; Raymond Thertulian; Guido Tricot; William Barlow; Erik Rasmussen; John Crowley; Bart Barlogie; Shaughnessy John


Blood | 2006

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

John D. Shaughnessy; Jeff Haessler; Jerry Zeldis; Yongsheng Huang; Fenghuang Zhan; Jeffrey R. Sawyer; Elias Anaissie; Frits van Rhee; Guido Tricot; Joshua Epstein; Maurizio Zangari; Mauricio Pineda-Roman; Klaus Hollmig; John Crowley; Bart Barlogie

Collaboration


Dive into the Yongsheng Huang's collaboration.

Top Co-Authors

Avatar

Fenghuang Zhan

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Bart Barlogie

University of Arkansas at Little Rock

View shared research outputs
Top Co-Authors

Avatar

John D. Shaughnessy

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Guido Tricot

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Crowley

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Frits van Rhee

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Klaus Hollmig

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

James P. Stewart

University of Arkansas for Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge